MedMira Invited to Attend Exclusive Conference on Military and Civilian Pre-Hospital Trauma Management
18 June 2012 - 3:22AM
PR Newswire (Canada)
HALIFAX, June 18, 2012 /CNW/ - MedMira Inc., (MedMira) , a
developer of rapid diagnostic technology and solutions, announced
today it has been invited to participate in an exclusive conference
taking place June 19-21, 2012, in Norway focused on both military
and civilian pre-hospital trauma management. The Remote
Damage Control Resuscitation (RDCR) Conference is organized by The
Norwegian Naval Special Operation Commando and the Norwegian Air
Ambulance Foundation. This three day symposium brings
together leading military and civilian medical professionals and
researchers in the field to share best practices on pre-hospital
trauma and life-threatening haemorrhage management. "This is the
first year we have invited both civilian and military speakers. We
recognize that military and civilian pre-hospital trauma management
differs in many ways, but there are probably more issues that bring
us together than pull us apart. We therefore want both civilian and
military perspectives to be presented," said Dr. Geir Strandenes,
Senior Medical Officer with the Norwegian Naval Special Operation
Commando, a leading researcher in pre-hospital whole blood
transfusion, and the principal investigator of the Blood Far
Forward research program. RDCR involves the assessment and
treatment of individuals severely wounded in the field, either in a
combat situation or a civilian disaster, where evacuation to a
hospital is only possible following stabilization by individuals
trained in acute trauma care. In far forward settings there
are no traditional laboratory screening mechanisms accessible to
screen donated blood and previously collected donor blood is not
readily available. It is here that advanced healthcare tools
like MedMira rapid tests become a critical piece of the RDCR
method, where the use of fresh whole blood products may be the only
lifesaving option prior to evacuation. "Connecting with this world
class group of medical, scientific and research professionals is an
excellent opportunity to further illustrate the unique features of
MedMira's advanced rapid diagnostic technology and the benefits it
can bring to both combat casualty care and civilian disaster
preparedness," said Hermes Chan, CEO, MedMira Inc. "Our
ongoing work with the U.S. Army and the Canadian Armed Forces
clearly demonstrates that MedMira rapid diagnostics can play a
critical role in the treatment of individuals critically wounded in
combat. The relationships we have built within these
organizations have led us to this opportunity in Norway and we look
forward to further collaboration with Dr. Strandenes and his
colleagues." To learn more about the RDCR Conference visit
www.wholebloodresearch.com. About MedMira MedMira is a leading
developer and manufacturer of flow-through rapid diagnostics and
technologies. The Company's tests provide hospitals, labs, clinics
and individuals with reliable, rapid diagnosis for diseases such as
HIV and hepatitis B and C in just three minutes. The company's
tests are sold under the Reveal®, Multiplo™ and Miriad brands in
global markets. MedMira's rapid flow-through HIV test is the only
one in the world to achieve regulatory approvals in Canada, the
United States, China and the European Union. MedMira's corporate
offices and manufacturing facilities are located in Halifax, Nova
Scotia, Canada. For more information visit MedMira's website at
www.medmira.com. This news release contains forward-looking
statements, including statements relating to growth in the
Company's business, earnings and profitability, and trends in
demand for the Company's products, which involve risk and
uncertainties and reflect the Company's current expectation
regarding future events including statements regarding possible
future growth and new business opportunities. Actual events
could materially differ from those projected herein and depend on a
number of factors including, but not limited to, changing market
conditions, successful and timely completion of clinical studies,
uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from
time to time in the company quarterly filings. Neither TSX Venture
Exchange nor its Regulation Services Provider (as that term is
defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
MEDMIRA INC. CONTACT: MedMira Contact:Andrea Young, Corporate
CommunicationsTel: 902-450-1588Email: ayoung@medmira.com
Copyright
MedMira (TSXV:MIR)
Historical Stock Chart
From Jun 2024 to Jul 2024
MedMira (TSXV:MIR)
Historical Stock Chart
From Jul 2023 to Jul 2024